The rationale for this pharmacokinetic (PK) study is to determine the PK parameters for Lu AA21004 (Vortioxetine) in the Chinese population.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
16
10 mg immediate-release (IR), one single dose, orally
CN001
Tianjin, China
PK AUC determination of Lu AA21004 (Vortioxetine)
Area under the curve (AUC)
Time frame: 11 days
PK Cmax determination of Lu AA21004 (Vortioxetine)
Maximum observed concentration (Cmax)
Time frame: 11 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.